Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137006 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT01137006: Completed Phase 1 study of Malignant Melanoma, sponsored by Eli Lilly and Company.
NCT01137006 is a Phase 1 study of Malignant Melanoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 27 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01137006, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
Primary Outcome
The MTD was defined as the dose preceding the dose level at which 2 participants experienced a dose-limiting toxicity (DLT) during treatment Cycle 1. A DLT was defined as any Grade 3 or above toxicity that emerged during study treatment and was clearly not attributable to malignant melanoma or co-medication and was possibly, probably, or definitely related to IMC-20D7S in the judgment of the investigator. No DLT was observed in the study; a provisional MTD was established.
Conditions Studied
Interventions
- BIOLOGICAL IMC-20D7S (Cohort 1A)
- BIOLOGICAL IMC-20D7S (Cohort 2A)
- BIOLOGICAL IMC-20D7S (Cohort 3A)
- BIOLOGICAL IMC-20D7S (Cohort 4A)
- BIOLOGICAL IMC-20D7S (Cohort 1B)
Study Locations (2)
Massachusetts
- ImClone Investigational Site - Boston
New York
- ImClone Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
What the finished NCT01137006 record still lists
NCT01137006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 5 interventions - of which IMC-20D7S (Cohort 1A) is the first listed.
NCT01137006 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT01137006 about?
NCT01137006 is a clinical study titled "An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma". A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.
What is the current status of trial NCT01137006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-06. Estimated completion is 2012-08.
What conditions does trial NCT01137006 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT01137006?
The interventions under investigation include: IMC-20D7S (Cohort 1A) (BIOLOGICAL), IMC-20D7S (Cohort 2A) (BIOLOGICAL), IMC-20D7S (Cohort 3A) (BIOLOGICAL), IMC-20D7S (Cohort 4A) (BIOLOGICAL), IMC-20D7S (Cohort 1B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01137006?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137006 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01137006's enrollment target sits among peer trials
27 21st of 28 higher than 8 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia